すべての画像(1)
About This Item
実験式（ヒル表記法）:
C19H12O8
CAS番号:
分子量:
368.29
EC Number:
MDL番号:
UNSPSCコード:
41116107
PubChem Substance ID:
NACRES:
NA.25
おすすめの製品
生物化学的／生理学的作用
Diacerin is an inhibitor of Interleukin-1B (IL-1B) production.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
ターゲットの組織
Respiratory system
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
個人用保護具 (PPE)
dust mask type N95 (US), Eyeshields, Gloves
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
D9302-10MG:
D9302-VAR:
D9302-BULK:
D9302-50MG:
Juliana Saibt Martins Pasin et al.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], 59(3), 189-196 (2009-09-05)
To investigate the effect of diacerein, an anti-inflammatory drug, on body temperature and protocols of fever induction in male Wistar rats. The effect of diacerein (5.0 mg/kg, s.c.) on rectal temperature (T (R)) changes induced by Baker's yeast (0.135 g/kg
Amit Kumar Aggarwal et al.
Drug development and industrial pharmacy, 37(10), 1181-1191 (2011-04-01)
Diacerein (DCN) is a new anti-inflammatory analgesic and antipyretic drug developed specially for the treatment of osteoarthritis. DCN is a poorly water-soluble drug with relatively low bioavailability. Therefore, the purpose of this study was to enhance the solubility and dissolution
Olivier Bruyère et al.
BMC musculoskeletal disorders, 9, 165-165 (2008-12-18)
Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last decade. The objective of this study is to prepare a document providing recommendations for the use of SYSADOA in osteoarthritis (OA). The following interventions were taken into consideration: avocado/soybean
Pascal Richette
La Revue du praticien, 62(5), 654-660 (2012-06-27)
According to the European League of Associations of Rheumatology (EULAR) and the American College of Rheumatology (ACR), acetaminophen should be used as a first-line therapy in patients with osteoarthritis, because of its safety and effectiveness. NSAID should be considered in
Achint Jain et al.
Journal of biomedical nanotechnology, 9(5), 891-900 (2013-06-28)
Osteoarthritis is the most common, multi component joint disease mainly characterized by destruction of articular cartilage which leads up to subchondral bone. Current treatment by NSAID's gives only symptomatic relief but semi-synthetic anthraquinone diacerein is novel chondroprotective agent intended for
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）